Results 81 to 90 of about 1,142,931 (269)
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
Therapeutic Advances in Medical Oncology, 2011 Introduction: Denosumab, a fully human monoclonal antibody, targets the receptor activator of nuclear factor-kappaB (RANK) ligand, a protein essential for osteoclast differentiation, activity and survival.
Guenther G. Steger, Rupert Bartsch
doaj +1 more source
The Roadmap of RANKL/RANK Pathway in Cancer
, 2021 The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling.
Sandra Casimiro +7 more
core +1 more source
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
Molecular Oncology, EarlyView.This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
The Role of Myeloma Cells to Osteoclast Activation [PDF]
Cell Journal, 2010 Objective: Multiple myeloma (MM) is a hematological malignancy characterized by osteolyticbone disease which is associated with severe bone pain and pathological bonefractures.
Bahare Sadeghi +5 more
doaj
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
RANK ligand converts the NCoR/HDAC3 co-repressor to a PGC1β- and RNA-dependent co-activator of osteoclast gene expression. [PDF]
Mol Cell, 2023 Abe Y +27 more
europepmc +1 more source
USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES
Brazilian Journal of Oncology, 2019 Giant-cell tumor is a relatively rare neoplasia, benign but locally aggressive, that causes significant bone destruction with predilection for epiphyseal and metaphyseal regions of long bones and the spine. Definitive treatment is surgical, with complete
Tamise da Silva Baptista +5 more
doaj +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Bulletin of the Chemical Society of Ethiopia, 2014 The complex formation between a newly synthesized tripodal ligand and the cation Cu2+ in water and surfactant media was studied spectrophotometrically using rank annihilation factor analysis (RAFA).
R. Golbedaghi, F. Khajavi
doaj +1 more source